

Anna Falanga

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4792752/publications.pdf>

Version: 2024-02-01

197
papers

16,790
citations

22153

59
h-index

15732

125
g-index

207
all docs

207
docs citations

207
times ranked

17062
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2950-2973.	2.8	2,392
2	Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2020, 38, 496-520.	1.6	971
3	Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014. <i>Journal of Clinical Oncology</i> , 2015, 33, 654-656.	1.6	911
4	American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 5490-5505.	1.6	875
5	Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2013, 31, 2189-2204.	1.6	717
6	Cancer and venous thromboembolism. <i>Lancet Oncology</i> , The, 2005, 6, 401-410.	10.7	525
7	2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. <i>Lancet Oncology</i> , The, 2019, 20, e566-e581.	10.7	458
8	Coagulation and cancer: biological and clinical aspects. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 223-233.	3.8	377
9	Molecular Basis for the Relationship Between Thrombosis and Cancer. <i>Thrombosis Research</i> , 2001, 102, V215-V224.	1.7	303
10	Myeloproliferative neoplasms and thrombosis. <i>Blood</i> , 2013, 122, 2176-2184.	1.4	303
11	Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. <i>Blood</i> , 2012, 119, 933-939.	1.4	260
12	Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. <i>Blood</i> , 2000, 96, 4261-4266.	1.4	259
13	Pathophysiology of the Thrombophilic State in the Cancer Patient. <i>Seminars in Thrombosis and Hemostasis</i> , 1999, 25, 173-182.	2.7	231
14	Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. <i>Biochemistry</i> , 1985, 24, 5558-5567.	2.5	217
15	The Impact of All-trans-Retinoic Acid on the Coagulopathy of Acute Promyelocytic Leukemia. <i>Blood</i> , 1998, 91, 3093-3102.	1.4	213
16	Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. <i>Experimental Hematology</i> , 2005, 33, 523-530.	0.4	212
17	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1004-1024.	3.4	206
18	Mechanisms and risk factors of thrombosis in cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 118, 79-83.	4.4	183

#	ARTICLE	IF	CITATIONS
19	Venous Thromboembolism in the Hematologic Malignancies. <i>Journal of Clinical Oncology</i> , 2009, 27, 4848-4857.	1.6	179
20	V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. <i>Experimental Hematology</i> , 2007, 35, 702-711.	0.4	169
21	Venous Thromboembolism Prophylaxis and Treatment in Cancer: A Consensus Statement of Major Guidelines Panels and Call to Action. <i>Journal of Clinical Oncology</i> , 2009, 27, 4919-4926.	1.6	162
22	Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation.. <i>Thrombosis and Haemostasis</i> , 2011, 106, 868-876.	3.4	158
23	Procoagulant mechanisms in tumour cells. <i>Best Practice and Research in Clinical Haematology</i> , 2009, 22, 49-60.	1.7	146
24	Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. <i>Blood</i> , 2008, 112, 4061-4068.	1.4	136
25	Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study. <i>British Journal of Haematology</i> , 2005, 129, 811-817.	2.5	134
26	Deep vein thrombosis in cancer: the scale of the problem and approaches to management. <i>Annals of Oncology</i> , 2005, 16, 696-701.	1.2	132
27	Thrombophilia in Cancer. <i>Seminars in Thrombosis and Hemostasis</i> , 2005, 31, 104-110.	2.7	131
28	Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1597-1628.	3.4	131
29	Cancer-associated venous thromboembolism. <i>Nature Reviews Disease Primers</i> , 2022, 8, 11.	30.5	130
30	Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1297-1302.	3.8	129
31	Disseminated Intravascular Coagulation in Acute Leukemia. <i>Seminars in Thrombosis and Hemostasis</i> , 2001, 27, 593-604.	2.7	123
32	Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia. <i>Haematologica</i> , 2009, 94, 911-918.	3.5	121
33	Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells. <i>Leukemia</i> , 2003, 17, 1636-1642.	7.2	115
34	Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Oncology Practice</i> , 2015, 11, e442-e444.	2.5	115
35	The mechanisms of cancer-associated thrombosis. <i>Thrombosis Research</i> , 2015, 135, S8-S11.	1.7	114
36	All-trans RETINOIC ACID INCREASES ADHESION TO ENDOTHELIUM OF THE HUMAN PROMYELOCYTIC LEUKAEMIA CELL LINE NB4. <i>British Journal of Haematology</i> , 1996, 93, 360-366.	2.5	113

#	ARTICLE	IF	CITATIONS
37	The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1772-1778.	3.8	107
38	Pathogenesis of Thrombosis in Patients with Malignancy. <i>International Journal of Hematology</i> , 2001, 73, 137-144.	1.6	102
39	Thrombotic disease in the myeloproliferative neoplasms. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 571-581.	2.5	102
40	Thrombosis associated with angiogenesis inhibitors. <i>Best Practice and Research in Clinical Haematology</i> , 2009, 22, 115-128.	1.7	100
41	ISTH guidelines for antithrombotic treatment in COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2214-2225.	3.8	100
42	Mechanisms of thrombosis in cancer. <i>Thrombosis Research</i> , 2013, 131, S59-S62.	1.7	94
43	<i>FANCM</i> c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. <i>Human Molecular Genetics</i> , 2015, 24, 5345-5355.	2.9	91
44	Pathogenesis of Thrombosis in Essential Thrombocythemia and Polycythemia Vera: The Role of Neutrophils. <i>Seminars in Hematology</i> , 2005, 42, 239-247.	3.4	86
45	Pathogenetic Mechanisms of Thrombosis in Malignancy. <i>Acta Haematologica</i> , 2001, 106, 18-24.	1.4	85
46	Thrombosis in Myeloproliferative Neoplasms. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 348-358.	2.7	84
47	Cancer Tissue Procoagulant Mechanisms and the Hypercoagulable State of Patients with Cancer. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 756-764.	2.7	84
48	Monitoring thrombin generation: Is addition of corn trypsin inhibitor needed?. <i>Thrombosis and Haemostasis</i> , 2009, 101, 1156-1162.	3.4	83
49	A Multidisciplinary Approach on the Perioperative Antithrombotic Management of Patients With Coronary Stents Undergoing Surgery. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 417-434.	2.9	81
50	Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin. <i>Thrombosis Research</i> , 2008, 121, 637-645.	1.7	80
51	Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera. <i>American Journal of Hematology</i> , 2011, 86, 337-342.	4.1	78
52	Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. <i>Blood</i> , 2000, 96, 4261-6.	1.4	77
53	Clotting mechanisms and cancer: implications in thrombus formation and tumor progression. <i>Clinical Advances in Hematology and Oncology</i> , 2003, 1, 673-8.	0.3	75
54	The coagulopathy of cancer. <i>Current Opinion in Hematology</i> , 2014, 21, 423-429.	2.5	74

#	ARTICLE	IF	CITATIONS
55	Bleeding and thrombosis in acute leukemia: What does the future of therapy look like?. <i>Thrombosis Research</i> , 2007, 120, S99-S106.	1.7	73
56	Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2003, 16, 463-482.	1.7	65
57	Prospective study of hemostatic alterations in children with acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2010, 85, 325-330.	4.1	64
58	Epidemiology, risk and outcomes of venous thromboembolism in cancer. <i>Hamostaseologie</i> , 2012, 32, 115-125.	1.9	64
59	Overview of the Postulated Mechanisms Linking Cancer and Thrombosis. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2007, 36, 122-130.	0.3	63
60	Hemostatic complications of angiogenesis inhibitors in cancer patients. <i>American Journal of Hematology</i> , 2008, 83, 862-870.	4.1	62
61	JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients. <i>Blood</i> , 2011, 118, 2599-2601.	1.4	61
62	Coagulopathy of Acute Promyelocytic Leukemia. <i>Acta Haematologica</i> , 2001, 106, 43-51.	1.4	60
63	Hypercoagulability and Tissue Factor Gene Upregulation in Hematologic Malignancies. <i>Seminars in Thrombosis and Hemostasis</i> , 2008, 34, 204-210.	2.7	59
64	Pathophysiology 1. Mechanisms of Thrombosis in Cancer Patients. <i>Cancer Treatment and Research</i> , 2019, 179, 11-36.	0.5	56
65	Venous thromboembolism in the hematologic malignancies. <i>Current Opinion in Oncology</i> , 2012, 24, 702-710.	2.4	55
66	Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. <i>Hematological Oncology</i> , 2018, 36, 624-632.	1.7	55
67	A Validated Risk Score for Venous Thromboembolism Is Predictive of Cancer Progression and Mortality. <i>Oncologist</i> , 2016, 21, 861-867.	3.7	54
68	Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 267-277.	2.1	54
69	Heparin in Tumor Progression and Metastatic Dissemination. <i>Seminars in Thrombosis and Hemostasis</i> , 2007, 33, 688-694.	2.7	53
70	Cancer, thrombosis and heparin-induced thrombocytopenia. <i>Thrombosis Research</i> , 2007, 120, S137-S140.	1.7	53
71	Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemia. <i>American Journal of Hematology</i> , 2014, 89, 68-73.	4.1	53
72	Management of Thrombohemorrhagic Syndromes (THS) in Hematologic Malignancies. <i>Hematology American Society of Hematology Education Program</i> , 2007, 2007, 165-171.	2.5	51

#	ARTICLE	IF	CITATIONS
73	The Incidence and Risk of Venous Thromboembolism Associated With Cancer and Nonsurgical Cancer Treatment. <i>Cancer Investigation</i> , 2009, 27, 105-115.	1.3	51
74	Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms. <i>Thrombosis and Haemostasis</i> , 2010, 104, 151-156.	3.4	51
75	Microparticles in tumor progression. <i>Thrombosis Research</i> , 2012, 129, S132-S136.	1.7	50
76	Thrombotic disease in the myeloproliferative neoplasms. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 571-81.	2.5	48
77	Human breast and colon carcinomas express cysteine proteinase activities with pro-aggregating and pro-coagulant properties. <i>International Journal of Cancer</i> , 1988, 42, 554-557.	5.1	46
78	Prevention of venous thromboembolism in patients with cancer: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISST)1. <i>Thrombosis Research</i> , 2012, 129, e171-e176.	1.7	46
79	Characterization of the thrombin generation potential of leukemic and solid tumor cells by calibrated automated thrombography. <i>Haematologica</i> , 2012, 97, 1173-1180.	3.5	44
80	Italian intersociety consensus on DOAC use in internal medicine. <i>Internal and Emergency Medicine</i> , 2017, 12, 387-406.	2.0	44
81	Cancer and Venous Thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , 2006, 32, 694-699.	2.7	43
82	Anticancer treatment and thrombosis. <i>Thrombosis Research</i> , 2012, 129, 353-359.	1.7	43
83	Hemostatic biomarkers in cancer progression. <i>Thrombosis Research</i> , 2018, 164, S54-S61.	1.7	43
84	ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera. <i>Thrombosis Research</i> , 2013, 132, 88-93.	1.7	41
85	Managing reversal of direct oral anticoagulants in emergency situations. <i>Thrombosis and Haemostasis</i> , 2016, 116, 1003-1010.	3.4	39
86	Activation of Clotting Factors in Cancer. <i>Cancer Treatment and Research</i> , 2009, 148, 31-41.	0.5	39
87	Inefficacy of intravenous immunoglobulin in patients with low-risk thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome. <i>American Journal of Hematology</i> , 1992, 41, 165-169.	4.1	38
88	Leukocytosis, JAK2 ^{V617F} Mutation, and Hemostasis in Myeloproliferative Disorders. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2007, 36, 148-159.	0.3	36
89	Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study. <i>Oncologist</i> , 2018, 23, 1372-1381.	3.7	36
90	The Decanucleotide Insertion/Deletion Polymorphism in the Promoter Region of the Coagulation Factor VII Gene and the Risk of Familial Myocardial Infarction. <i>Thrombosis Research</i> , 2000, 98, 9-17.	1.7	33

#	ARTICLE	IF	CITATIONS
91	Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update Summary. <i>Journal of Oncology Practice</i> , 2019, 15, 661-664.	2.5	33
92	Aspirin increases the bleeding side effects in essential thrombocythemia independent of the cyclooxygenase pathway: Role of the lipoxygenase pathway. , 1998, 57, 277-282.		32
93	Mechanisms of Hypercoagulation in Malignancy and during Chemotherapy. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 1998, 28, 50-60.	0.3	31
94	Differential effect of the low-molecular-weight heparin, dalteparin, and unfractionated heparin on microvascular endothelial cell hemostatic properties. <i>Haematologica</i> , 2006, 91, 207-14.	3.5	31
95	Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELDâ€VTE patients. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1694-1706.	3.8	30
96	PATHOGENESIS AND TREATMENT OF THROMBOHEMORRHAGIC DIATHESIS IN ACUTE PROMYELOCYTIC LEUKEMIA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011, 3, e2011068.	1.3	29
97	Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer: the HYPERCAN study. <i>Thrombosis Research</i> , 2016, 140, S55-S59.	1.7	29
98	EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer. <i>HemaSphere</i> , 2022, 6, e750.	2.7	29
99	Molecular biomarkers of thrombosis in myeloproliferative neoplasms. <i>Thrombosis Research</i> , 2016, 140, S71-S75.	1.7	28
100	Proteolysis of von Willebrand factor is decreased in acute promyelocytic leukaemia by treatment with allâ€transâ€retinoic acid. <i>British Journal of Haematology</i> , 1996, 92, 733-739.	2.5	27
101	The effect of anticoagulant drugs on cancer. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 1263-1265.	3.8	26
102	The prevention and management of asparaginaseâ€related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 278-284.	3.8	26
103	PALB2 sequencing in Italian familial breast cancer cases reveals a high-risk mutation recurrent in the province of Bergamo. <i>Genetics in Medicine</i> , 2014, 16, 688-694.	2.4	25
104	Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper. <i>Blood Cancer Journal</i> , 2019, 9, 61.	6.2	25
105	Laboratory haemostasis monitoring in COVIDâ€19. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2058-2060.	3.8	25
106	LMWH Bemiparin and ULMWH RO-14 Reduce the Endothelial Angiogenic Features Elicited by Leukemia, Lung Cancer, or Breast Cancer Cells. <i>Cancer Investigation</i> , 2011, 29, 153-161.	1.3	24
107	The SAME-TT2R2 score predicts the quality of anticoagulation control in patients with acute VTE. <i>Thrombosis and Haemostasis</i> , 2016, 115, 1101-1108.	3.4	24
108	Activated prothrombin complex concentrate (<sc>FEIBA</sc> ^{Â®}) in acquired haemophilia A: a large multicentre Italian study â€ the <sc>FAIR</sc> Registry. <i>British Journal of Haematology</i> , 2019, 184, 853-855.	2.5	24

#	ARTICLE	IF	CITATIONS
109	All-trans retinoic acid modulates microvascular endothelial cell hemostatic properties. <i>Haematologica</i> , 2003, 88, 895-905.	3.5	24
110	Effect of anticoagulant drugs in cancer. <i>Current Opinion in Pulmonary Medicine</i> , 2005, 11, 403-407.	2.6	23
111	Defining the Thrombotic Risk in Patients with Myeloproliferative Neoplasms. <i>Scientific World Journal</i> , The, 2011, 11, 1131-1137.	2.1	23
112	Monitoring thrombin generation: is addition of corn trypsin inhibitor needed?. <i>Thrombosis and Haemostasis</i> , 2009, 101, 1156-62.	3.4	23
113	Several murine metastasizing tumors possess a cysteine proteinase with cancer procoagulant characteristics. <i>International Journal of Cancer</i> , 1987, 39, 774-777.	5.1	21
114	Treatment of venous thromboembolism in patients with cancer: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISST). <i>Thrombosis Research</i> , 2009, 124, e32-e40.	1.7	21
115	Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancer. <i>Haematologica</i> , 2020, 105, 1704-1711.	3.5	21
116	A microphysiological early metastatic niche on a chip reveals how heterotypic cell interactions and inhibition of integrin subunit $\beta 3$ impact breast cancer cell extravasation. <i>Lab on A Chip</i> , 2021, 21, 1061-1072.	6.0	21
117	The COVID-19 Pandemic and the Need for an Integrated and Equitable Approach: An International Expert Consensus Paper. <i>Thrombosis and Haemostasis</i> , 2021, 121, 992-1007.	3.4	21
118	Comparison of properties of cancer procoagulant and human amnion-chorion procoagulant. <i>BBA - Proteins and Proteomics</i> , 1985, 831, 161-165.	2.1	19
119	Type and dose of heparin in Covid-19: Reply. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2063-2064.	3.8	19
120	All-Trans-Retinoic Acid and Bleeding/Thrombosis. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2003, 33, 19-21.	0.3	18
121	Management of Cancer-Associated Thrombosis: Unmet Needs and Future Perspectives. <i>TH Open</i> , 2021, 05, e376-e386.	1.4	18
122	Anticoagulants and Cancer Survival. <i>Seminars in Thrombosis and Hemostasis</i> , 2006, 32, 810-813.	2.7	17
123	Platelet-mediated proteolytic down regulation of the anticoagulant activity of protein S in individuals with haematological malignancies. <i>Thrombosis and Haemostasis</i> , 2012, 107, 468-476.	3.4	17
124	Antithrombotic medication in cancer-associated thrombocytopenia: Current evidence and knowledge gaps. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 132, 76-88.	4.4	17
125	Thrombin generation predicts early recurrence in breast cancer patients. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2220-2231.	3.8	17
126	Hemostatic System Activation in Patients with Lupus Anticoagulant and Essential Thrombocythemia. <i>Seminars in Thrombosis and Hemostasis</i> , 1994, 20, 324-327.	2.7	16

#	ARTICLE	IF	CITATIONS
127	Thrombosis and Cancer: Emerging Data for the Practicing Oncologist. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, e337-e345.	3.8	16
128	Inhibition of cancer procoagulant by peptidyl diazomethyl ketones and peptidyl sulfonium salts. Thrombosis Research, 1989, 54, 389-398.	1.7	15
129	Effect of all-trans-Retinoic acid on the hypercoagulable state of patients with breast cancer. American Journal of Hematology, 2002, 70, 9-15.	4.1	15
130	Blood oxidative status and selectins plasma levels in healthy donors receiving granulocyte-colony stimulating factor. Leukemia, 2006, 20, 1430-1434.	7.2	15
131	All trans-retinoic acid modulates the procoagulant activity of human breast cancer cells. Thrombosis Research, 2011, 128, 368-374.	1.7	15
132	Comparative assessment of low-molecular-weight heparins in cancer from the perspective of patient outcomes and survival. Patient Related Outcome Measures, 2011, 2, 175.	1.2	15
133	Hemostatic biomarkers in occult cancer and cancer risk prediction. Thrombosis Research, 2020, 191, S37-S42.	1.7	15
134	Low levels of ADAMTS-13 with high anti-ADAMTS-13 antibodies during remission of immune-mediated thrombotic thrombocytopenic purpura highly predict for disease relapse: A multi-institutional study. American Journal of Hematology, 2020, 95, 953-959.	4.1	14
135	Long Term Low Molecular Weight Heparin Anticoagulant Therapy Modulates Thrombin Generation and D-dimer in Patients with Cancer and Venous Thromboembolism. Cancer Investigation, 2017, 35, 490-499.	1.3	13
136	Acute promyelocytic leukemia cell adhesion to vascular endothelium is reduced by heparins. Annals of Hematology, 2018, 97, 1555-1562.	1.8	13
137	Predicting APL lethal bleeding in the ATRA era. Blood, 2017, 129, 1739-1740.	1.4	12
138	Prevention and Management of Thrombosis in BCR/ABL-Negative Myeloproliferative Neoplasms. Hamostaseologie, 2021, 41, 048-057.	1.9	12
139	Biological and Clinical Aspects of Anticancer Effects of Antithrombotics. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2003, 33, 389-392.	0.3	11
140	Tissue Factor Expression on Platelet Surface during Preparation and Storage of Platelet Concentrates. Transfusion Medicine and Hemotherapy, 2013, 40, 126-132.	1.6	11
141	Haplotype analyses of the c.1027C>T and c.2167_2168delAT recurrent truncating mutations in the breast cancer-predisposing gene PALB2. Breast Cancer Research and Treatment, 2016, 160, 121-129.	2.5	11
142	Two Missense Variants Detected in Breast Cancer Probands Preventing BRCA2-PALB2 Protein Interaction. Frontiers in Oncology, 2018, 8, 480.	2.8	11
143	Fundamental Research in Oncology and Thrombosis 2 (FRONTLINE 2): A Follow-Up Survey. Oncologist, 2020, 25, e1091-e1097.	3.7	10
144	The predictive value of D-dimer measurement for cancer in patients with deep vein thrombosis. Haematologica, 2005, 90, 149.	3.5	10

#	ARTICLE	IF	CITATIONS
145	Procoagulant activity of mouse transformed cells: Different expression in freshly isolated or cultured cells. <i>In Vitro Cellular & Developmental Biology</i> , 1988, 24, 1154-1158.	1.0	9
146	INTRAVENOUS GAMMAGLOBULIN, ANTIPHOSPHOLIPID ANTIBODIES, AND THROMBOCYTOPENIA. <i>Lancet</i> , The, 1988, 332, 969.	13.7	9
147	Thrombophilic status may predict prognosis in patients with metastatic BRAFV600-mutated melanoma who are receiving BRAF inhibitors. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 1254-1256.e4.	1.2	9
148	Validation of the Role of Thrombin Generation Potential by a Fully Automated System in the Identification of Breast Cancer Patients at High Risk of Disease Recurrence. <i>TH Open</i> , 2021, 05, e56-e65.	1.4	9
149	Thrombosis and Cancer: Emerging Data for the Practicing Oncologist. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , e337-e345.	3.8	9
150	ASPIRIN INHIBITS PLATELET AGGREGATION BUT NOT BECAUSE IT PREVENTS THROMBOXANE SYNTHESIS. <i>Lancet</i> , The, 1982, 320, 775.	13.7	8
151	Treatment of thromboembolism in cancer patients. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2049-2058.	1.8	8
152	Hemostatic Biomarkers and Cancer Prognosis: Where Do We Stand?. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 962-971.	2.7	8
153	Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. <i>Blood</i> , 2000, 96, 4261-4266.	1.4	8
154	Platelet haemostatic properties in β^2 -thalassaemia: the effect of blood transfusion. <i>Blood Transfusion</i> , 2017, 15, 413-421.	0.4	8
155	Thrombosis in myeloproliferative neoplasms: A clinical and pathophysiological perspective. <i>Thrombosis Update</i> , 2021, 5, 100081.	0.9	8
156	Circulating microparticles in children with sickle cell anemia: a heterogeneous procoagulant storm directed by hemolysis and fetal hemoglobin. <i>Haematologica</i> , 2013, 98, 995-997.	3.5	7
157	Anticoagulation in thrombocytopenic patients with hematological malignancy: A multinational clinical vignette-based experiment. <i>European Journal of Internal Medicine</i> , 2020, 77, 86-96.	2.2	7
158	The extension of disease is associated to an increased risk of venous thromboembolism (VTE) in patients with gastrointestinal (GI) carcinoma. <i>Thrombosis and Haemostasis</i> , 2006, 95, 752-754.	3.4	7
159	Evaluation of nucleated red blood cell count by Sysmex XE-2100 in patients with thalassaemia or sickle cell anaemia and in neonates. <i>Blood Transfusion</i> , 2015, 13, 588-94.	0.4	7
160	Treatment of venous thromboembolism with tinzaparin in oncological patients. <i>Minerva Medica</i> , 2019, 110, 251-258.	0.9	6
161	Thrombosis and malignancy: an underestimated problem. <i>Haematologica</i> , 2003, 88, 607-10.	3.5	6
162	Fibrinolytic Proteins and Factor XIII as Predictors of Thrombotic and Hemorrhagic Complications in Hospitalized COVID-19 Patients. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	6

#	ARTICLE	IF	CITATIONS
163	Acquired Autoimmune Hemophilia Following SARS-CoV-2 Vaccines: Dual-Drug Effects on Blood Coagulation and the Scylla and Charybdis Phenomenon. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1555-1557.	3.4	5
164	Platelet Cut-Off For Anticoagulant Therapy In Cancer Patients With Venous Thromboembolism and Thrombocytopenia: An Expert Opinion Based On RAND/UCLA Appropriateness Method (RAM). <i>Blood</i> , 2013, 122, 581-581.	1.4	5
165	Tissue Plasminogen Activator Levels and Risk of Breast Cancer in a Caseâ€“Cohort Study on Italian Women: Results from the Moli-sani Study. <i>Thrombosis and Haemostasis</i> , 2021, 121, 449-456.	3.4	5
166	Summary and Conclusions. Pathophysiology of Haemostasis and Thrombosis: <i>International Journal on Haemostasis and Thrombosis Research</i> , 2007, 36, 212-214.	0.3	4
167	Heparins inhibit the endothelial pro-thrombotic features induced by tumor cells. <i>Thrombosis Research</i> , 2017, 157, 55-57.	1.7	4
168	How well do European patients understand cancer-associated thrombosis? A patient survey. <i>Cancer Treatment and Research Communications</i> , 2022, 31, 100557.	1.7	4
169	Thrombotic complications in patients with cancer: Advances in pathogenesis, prevention, and treatmentâ€“A report from ICTHIC 2021. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12744.	2.3	4
170	Reply to T.H. Oo. <i>Journal of Clinical Oncology</i> , 2013, 31, 4381-4382.	1.6	3
171	APL Coagulopathy. , 2018, , 55-70.		3
172	Standardization of risk prediction model reporting in cancerâ€“associated thrombosis: Communication from the ISTHâ€“SSC subcommittee on hemostasis and malignancy. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1920-1927.	3.8	3
173	Vitamin K-Dependent Procoagulant in Cancer Cells: A Potential Target for the Antimetastatic Effect of Warfarin?. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 1986, 16, 288-294.	0.3	2
174	Eradication of acquired hemophilia associated with indolent non-Hodgkin lymphoma by a disease specific treatment. <i>Leukemia and Lymphoma</i> , 2015, 56, 3210-3212.	1.3	2
175	Mechanisms of Thrombogenesis. , 2012, , 57-67.		2
176	The Impact of All-trans-Retinoic Acid on the Coagulopathy of Acute Promyelocytic Leukemia. <i>Blood</i> , 1998, 91, 3093-3102.	1.4	2
177	Widespread Arterial Thrombosis after ChAdOx1 nCov-19 Vaccination. <i>Case Reports in Critical Care</i> , 2022, 2022, 1-4.	0.4	2
178	MPN and thrombosis was hard enough .â€“ now there's COVID-19 thrombosis too. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 710-717.	2.5	2
179	Coagulation in Hematological Malignancies. <i>Cancer Investigation</i> , 2009, 27, 7-16.	1.3	1
180	Management and Outcomes of Isolated Distal Deep Vein Thromboses: A Questionable Trend toward Long-Lasting Anticoagulation Treatment. Results from the START-Register. <i>TH Open</i> , 2021, 05, e239-e250.	1.4	1

#	ARTICLE	IF	CITATIONS
181	Hemostatic Markers, Adamts-13 Profile and Anti-Sars-Cov-2 Antibody Levels in Patients with Immune Thrombotic Thrombocytopenic Purpura Receiving BNT162b2 Vaccination. <i>Blood</i> , 2021, 138, 1022-1022.	1.4	1
182	Extensive Characterization of the Hemostatic Derangement Occurring in COVID-19 Patients Admitted to the Bergamo Hospital. <i>Blood</i> , 2020, 136, 36-36.	1.4	1
183	Venous thromboembolism in oncology. <i>Eksperymental'naïi, aïi, Onkologiii, aïi</i> , 2004, 26, 11-4.	0.1	1
184	Treatment Resistance Risk in Patients with Newly Diagnosed Multiple Myeloma Is Associated with Blood Hypercoagulability: The ROADMAP-MM Study. <i>Hemato</i> , 2022, 3, 188-203.	0.6	1
185	Evidence-Based Minireview: Are DOACs an alternative to vitamin K antagonists for treatment of venous thromboembolism in patients with MPN?. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 448-452.	2.5	1
186	Increased platelet thrombus formation under flow conditions in whole blood from polycythaemia vera patients. <i>Blood Transfusion</i> , 2021, , .	0.4	1
187	Preface. <i>Thrombosis Research</i> , 2012, 129, ix.	1.7	0
188	Preface. <i>Thrombosis Research</i> , 2016, 140, ix-x.	1.7	0
189	The International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC) at the Peak of Adolescence " 15 Years and Counting. <i>Thrombosis Research</i> , 2016, 140, S99-S102.	1.7	0
190	Preface. <i>Thrombosis Research</i> , 2018, 164, S1-S2.	1.7	0
191	Risk of Venous Thromboembolism in Surgical Elderly Patients. , 2018, , 65-78.		0
192	Preface to the Proceedings of the 10th International Conference on Thrombosis and Hemostasis Issues in Cancer, 2020. <i>Thrombosis Research</i> , 2020, 191, S1-S2.	1.7	0
193	Venous Thromboembolism and Cancer. , 2007, , 199-211.		0
194	Thrombin Generation and D-Dimer Significantly Predict for Early Disease Progression and Mortality in Patients with Gastrointestinal Cancer. <i>Blood</i> , 2020, 136, 32-32.	1.4	0
195	Editorial: Role of the Platelet Phenomenon in Cardiovascular Diseases and Cancer. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 859770.	2.4	0
196	The COMPASS-COVID-19-ICU Study: Identification of Factors to Predict the Risk of Intubation and Mortality in Patients with Severe COVID-19. <i>Hemato</i> , 2022, 3, 204-218.	0.6	0
197	Hemostatic system activation in breast cancer: Searching for new biomarkers for cancer risk prediction and outcomes. <i>Thrombosis Research</i> , 2022, 213, S46-S50.	1.7	0